

References

- Akil, M., Kolachana, B. S., Rothmond, D. A., et al. (2003). Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. *Journal of Neuroscience*, *23*, 2008–2013.
- Andreasen N. C., Ziebell S., Pierson R., Magnotta V. (2011, February). Long-term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia. Ho BC, *Arch Gen Psychiatry*, *68*(2): 128–137.
- Bauer, D., Gupta, D., Harotunian, V., Meador-Woodruff, J. H., & McCullumsmith, R. E. (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. *Schizophrenia Research*, *104*, 108–120.
- Bergeron, R., Imamura, Y., Frangioni, J. V., Greene, R. W., & Coyle, J. T. (2007). Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. *Journal of Neurochemistry*, *100*, 346–357.
- Bernstein, H. G., Steiner, J., & Bogerts, B. (2009). Glial cells in schizophrenia: Pathophysiological significance and possible consequences for therapy. *Expert Review of Neurotherapeutics*, *9*, 1059–1071.
- Brzustowicz, L. M. (2008). NOS1AP in schizophrenia. *Current Psychiatry Reports*, *10*, 158–163.
- Buonanno, A. (2010). The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits. *Brain Research Bulletin*, *83*, 122–131.
- Carlsson, A. (2001). A paradigm shift in brain research. *Science*, *294*, 1021–1024.
- Clay, H. B., Sullivan, S., & Konradi, C. (2011). Mitochondrial dysfunction and pathology in

- bipolar disorder and schizophrenia. *International Journal of Developmental Neuroscience*, 29, 311–324.
- Cornblatt, B. A., Lencz, T., Smith, C. W., et al. (2003). The schizophrenia prodrome revisited: A neurodevelopmental perspective. *Schizophrenia Bulletin*, 29, 633–651.
- Coyle, J. T. (1982). The clinical use of antipsychotic medications. *The Medical Clinics of North America*, 66, 993–1009.
- Coyle, J. T., Balu, D., Benneyworth, M., Basu, A., & Roseman, A. (2010). Beyond the dopamine receptor: Novel therapeutic targets for treating schizophrenia. *Dialogues Clinical Neuroscience*, 12, 359–382.
- Dager, S. R., Corrigan, N. M., Richards, T. L., & Posse, S. (2008). Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. *Topics in Magnetic Resonance Imaging*, 19, 81–96.
- Deniker, P. (1978). Impact of neuroleptic chemotherapies on schizophrenic psychoses. *The American Journal of Psychiatry*, 135, 923–927.
- Freyberg, Z., Ferrando, S. J., & Javitch, J. A. (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. *The American Journal of Psychiatry*, 167, 388–396.
- Gonzalez-Burgos, G., Hashimoto, T., & Lewis, D. A. (2010). Alterations of cortical GABA neurons and network oscillations in schizophrenia. *Current Psychiatry Reports*, 12, 335–344.
- Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? *The American Journal of Psychiatry*, 153, 321–330.
- Harrison, P. J., Law, A. J., & Eastwood, S. L. (2003). Glutamate receptors and transporters in the

- hippocampus in schizophrenia. *Annals of the New York Academy of Sciences*, 1003, 94–101.
- Heckers, S. (2001). Neuroimaging studies of the hippocampus in schizophrenia. *Hippocampus*, 11, 520–528.
- Howes, O. D., Egerton, A., Allan, V., McGuire, P., Stokes, P., & Kapur, S. (2009). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. *Current Pharmaceutical Design*, 15, 2550–2559.
- Jardri, R., Pouchet, A., Pins, D., & Thomas, P. (2011). Cortical activations during auditory verbal hallucinations in schizophrenia: A coordinate-based meta-analysis. *The American Journal of Psychiatry*, 168, 73–81.
- Karoutzou, G., Emrich, H. M., & Dietrich, D. E. (2008). The myelin-pathogenesis puzzle in schizophrenia: A literature review. *Molecular Psychiatry*, 13, 245–260.
- Kristiansen, L. V., Huerta, I., Beneyto, M., & Meador-Woodruff, J. H. (2007). NMDA receptors and schizophrenia. *Current Opinion in Pharmacology*, 7, 48–55.
- Krystal, J. H., D'Souza, D. C., Mathalon, D., et al. (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. *Psychopharmacology*, 169, 215–233.
- Kuperberg, G. R., Broome, M. R., McGuire, P. K., et al. (2003). Regionally localized thinning of the cerebral cortex in schizophrenia. *Archives of General Psychiatry*, 60, 878–888.
- Lencz, T., & Malhotra, A. K. (2009). Pharmacogenetics of antipsychotic-induced side effects. *Dialogues Clinical Neuroscience*, 11, 405–415.
- Leonard, S., Gault, J., Hopkins, J., et al. (2002). Association of promoter variants in the alpha7

- nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. *Archives of General Psychiatry*, *59*, 1085–1096.
- Lewis, D. A., & Lieberman, J. A. (2002). Catching up on schizophrenia: Natural history and neurobiology. *Neuron*, *28*, 325–334.
- Lewis, S., & Lieberman, J. A. (2008). CATIE and CUtLASS: Can we handle the truth? *The British Journal of Psychiatry*, *192*, 161–163.
- Li, B., Devidze, N., Barenegolts, D., Prostack, N., Sphicas, E., Apicella, A. J., Malinow, R., & Emamian, E. S. (2009). NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity. *Journal of Neuroscience*, *29*, 11965–11972.
- Liddle, P. F., Barnes, T. R., Morris, D., & Haque, S. (1989). Three syndromes in chronic schizophrenia. *The British Journal of Psychiatry Supplement*, *7*, 119–122.
- Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. *Trends in Neurosciences*, *31*, 234–242.
- Meltzer, H. Y. (2004). What's atypical about atypical antipsychotic drugs? *Current Opinion in Pharmacology*, *4*, 53–57.
- Puri, B. K. (2010). Progressive structural brain changes in schizophrenia. *Expert Review of Neurotherapeutics*, *10*, 33–42.
- Sacchi, S., Bernasconi, M., Martineau, M., Mothet, J. P., Ruzzene, M., Pilone, M. S., Pollegioni, L., & Molla, G. (2008). pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: Effect on schizophrenia susceptibility. *Journal of Biological Chemistry*, *283*, 22244–22256.

- Sawada, K., Young, C. E., Barr, A. M., et al. (2002). Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. *Molecular Psychiatry*, 7, 484–492.
- Seeman, P., & Van Tol, H. H. (1994). Dopamine receptor pharmacology. *Trends in Pharmacological Sciences*, 15, 264–270.
- Smesny, S., Rosburg, T., Nenadic, I., Fenk, K. P., Kunstmann, S., Rzanny, R., Volz, H. P., & Sauer, H. (2007). Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. *NeuroImage*, 35, 729–737.
- Snyder, S. H. (1976). The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. *The American Journal of Psychiatry*, 133, 197–202.
- Thaker, G. K. (2008). Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. *Schizophrenia Bulletin*, 34, 760–773.
- Tiwari, A. K., Zai, C. C., Müller, D. J., & Kennedy, J. L. (2010). Genetics in schizophrenia: Where are we and what next? *Dialogues Clinical Neuroscience*, 12, 289–303.
- Tsai, G. E., & Lin, P. Y. (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. *Current Pharmaceutical Design*, 16, 522–537.
- Tuetting, P., Doueiri, M. S., Guidotti, A., Davis, J. M., & Costa, E. (2006). Reelin down-regulation in mice and psychosis endophenotypes. *Neuroscience and Biobehavioral Reviews*, 30, 1065–1077.
- Weinberger, D. R., Berman, K. F., & Zec, R. F. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. *Archives of General Psychiatry*, 43, 114–124.
- Wonodi, I., & Swarcz, R. (2010). Cortical kynurenine pathway metabolism: A novel target for

cognitive enhancement in Schizophrenia. *Schizophrenia Bulletin*, 36, 211–218.